Pharmacoeconomics and Policy2026，Vol.2Issue(1)：P.38-45,8.DOI:10.1016/j.pharp.2026.03.004
Clinical burden and health-related quality of life in Chinese patients with mucopolysaccharidosis type Ⅱ under 16 years
Zixuan Lyu 1Min Li 2Yaqun Wang 1Pei Wang 3Shengnan Duan 4Huaxin Yu 5Kexin Li 6Jun Hu 7Ni Yuan8
作者信息
- 1. School of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China Dong Fureng Institute of Economic and Social Development,Wuhan University,Wuhan,430072,China
- 2. School of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China School of Public Health,Jiamusi University,Jiamusi,Heilongjiang,154007,China
- 3. School of Public Health,Fudan University,Shanghai,200433,China
- 4. School of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China School of Public Administration,Dongbei University of Finance&Economics,Dalian,Liaoning,116025,China
- 5. Disease Control and Prevention Center of Jinpu New Area(Health Supervision Institute),Dalian,Liaoning,116600,China
- 6. China Alliance for Rare Disease,Beijing,100020,China
- 7. Shanghai Center for Adverse Drug Reaction and Medical Device Monitoring,Shanghai,200040,China
- 8. School of Public Health,Dalian Medical University,Dalian,Liaoning,116044,China Innovative Drug Policy and medical Insurance Research Center,Dalian Medical University,Dalian,Liaoning,116044,China
- 折叠
摘要
关键词
MucopolysaccharidosesⅡ/HRQoL/PedsQL 4.0/Influencing factors/China分类
医药卫生引用本文复制引用
Zixuan Lyu,Min Li,Yaqun Wang,Pei Wang,Shengnan Duan,Huaxin Yu,Kexin Li,Jun Hu,Ni Yuan..Clinical burden and health-related quality of life in Chinese patients with mucopolysaccharidosis type Ⅱ under 16 years[J].Pharmacoeconomics and Policy,2026,2(1):P.38-45,8.
